Results 61 to 70 of about 10,491 (187)

Role of Raltegravir in HIV-1 Management

, 2012
OBJECTIVE: To review the literature concerning the role of raltegravir in the treatment of HIV-1 in antiretroviral (ARV)-experienced and ARV-naïve patients.
Sutton, S Scott, Bryant, Jacquelyn E, Rokas, Kristina E, Millisor, Vanessa E, Shamroe, Caitlin L, Bookstaver, P Brandon, Weissman, Sharon B   +6 more
core   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration

, 2010
BACKGROUND: Raltegravir and maraviroc represent new, important resources for HIV-infected patients with intolerance or resistance to other antiretroviral agents. The safety and efficacy of both drugs have been investigated, but there is no information on
CECCARELLI, GIANCARLO, Baroncelli S., Vullo V., REGAZZI M, GALLUZZO C, FRANCISCI D, Preziosi R., Villani P., CUSATO M, CICALINI S, Ladisa N., Floridia M., Francisci D., FLORIDIA M, VULLO, Vincenzo, Segala D., WEIMER LE, VILLANI P, Galluzzo C. M., TOMMASI C, Cicalini S., LADISA N, PREZIOSI R, Regazzi M., BARONCELLI S, Tommasi C., Cusato M., Weimer L. E.   +27 more
core   +1 more source

Brief Histories of Retroviral Integration Research and Associated International Conferences

Viruses
The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes.
Duane P. Grandgenett, Alan N. Engelman
doaj   +1 more source

Are new antiretroviral treatments increasing the risks of clinical obesity?

Journal of Virus Eradication, 2019
There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant.
Andrew Hill, Laura Waters, Anton Pozniak
doaj   +1 more source

Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study)

, 2011
We studied the penetration of raltegravir and HIV shedding in the genital tract among 14 HIV-1-infected women receiving a raltegravir-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA.
Houria Ichou, Laurent Mandelbrot, Cyril Clavel, Claudia Ferreira, Catherine Crenn-Hebert, Gilles Peytavin, Isabelle Heard, Christine Katlama, Roland Tubiana, Cathia Soulié, François Bissuel, Anne-Geneviève Marcelin   +11 more
core   +1 more source

Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens

Терапевтический архив, 2010
The paper gives the results of the largest international studies demonstrating the efficacy and safety of Raltegravir as part of antiretroviral treatment (ARVT) regimens in both patients starting therapy (STARTMRK study) and those pretreated with ...
Aleksey Viktorovich Kravchenko, A V Kravchenko   +1 more
doaj  

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not

Retrovirology, 2011
Background HIV-2 is endemic in West Africa and has spread throughout Europe. However, the alternatives for HIV-2-infected patients are more limited than for HIV-1.
Damond Florence, Collin Gilles, Storto Alexandre, Charpentier Charlotte, Delelis Olivier, Ni Xiao-Ju, Descamps Diane, Mouscadet Jean-François   +7 more
doaj   +1 more source

The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults [PDF]

, 2012
BACKGROUND: Dolutegravir (DTG, S/GSK1349572) is an integrase inhibitor with low nanomolar potency. Susceptibility to dolutegravir and raltegravir was determined for raltegravir-resistant clinical isolates. METHODS: Genotypic and phenotypic susceptibility
Johns, Brian A, Deeks, Steven G, Martin, Jeffrey N, Sato, Akihiko, Underwood, Mark R, Fujiwara, Tamio   +5 more
core   +1 more source

Antiretroviral therapy containing raltegravir to prevent mother-to-child transmission of HIV in infected pregnant women

Infectious Disease Reports, 2017
We conducted a retrospective study in a general hospital in Buenos Aires, Argentina (2009-2015) aimed at evaluating outcomes in HIV-infected pregnant women (HIPW), who were prescribed raltegravir (RAL)- containing antiretroviral therapy (ART). A total of
Diego M. Cecchini, Marina G. Martinez, Laura M. Morganti, Claudia G. Rodriguez   +3 more
doaj   +1 more source